Literature DB >> 1416832

Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae.

S Arai1, Y Gohara, K Kuwano, T Kawashima.   

Abstract

Fifty strains of Mycoplasma pneumoniae were tested for susceptibility to new quinolones, tetracyclines, and macrolides. Temafloxacin, ofloxacin, and ciprofloxacin possessed the most mycoplasmacidal activity against these organisms. The MBC for 50% of the strains (MBC50)-to-MIC50 ratio for each of these drugs was 4. The MBC50-to-MIC50 ratios for the tetracyclines and macrolides were markedly higher, within a range of 32 to 2,000. On the basis of these results, temafloxacin and ofloxacin might be promising antimicrobial agents for the treatment of mycoplasmal infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416832      PMCID: PMC190339          DOI: 10.1128/AAC.36.6.1322

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics.

Authors:  Y Niitu; S Hasegawa; T Suetake; H Kubota; S Komatsu; M Horikawa
Journal:  J Pediatr       Date:  1970-03       Impact factor: 4.406

Review 2.  The role of the microbiology laboratory in the treatment of infective endocarditis.

Authors:  C W Stratton
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

3.  Comparison of josamycin and erythromycin in the therapy of Mycoplasma pneumoniae pneumonia.

Authors:  R P Wenzel; J O Hendley; W K Dodd; J M Gwaltney
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

4.  Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.

Authors:  L Heifets; P Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.

Authors:  G H Cassell; K B Waites; M S Pate; K C Canupp; L B Duffy
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Sep-Oct       Impact factor: 2.803

Review 6.  Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria.

Authors:  E Tuomanen
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

7.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

8.  Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits.

Authors:  W M Scheld; M A Sande
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

9.  Effects of rokitamycin and other macrolide antibiotics on Mycoplasma pneumoniae in L cells.

Authors:  T Misu; S Arai; M Furukawa; Y Yamamoto; T Miyazaki
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

10.  In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors:  K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

View more
  13 in total

1.  In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.

Authors:  M Takahata; M Shimakura; R Hori; K Kizawa; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Novel paradigms for drug discovery: computational multitarget screening.

Authors:  Ekachai Jenwitheesuk; Jeremy A Horst; Kasey L Rivas; Wesley C Van Voorhis; Ram Samudrala
Journal:  Trends Pharmacol Sci       Date:  2008-01-10       Impact factor: 14.819

Review 3.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1993       Impact factor: 9.546

4.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

7.  In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.

Authors:  M Kaku; K Ishida; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; K Tomono; N Suyama
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.

Authors:  Y Gohara; S Arai; A Akashi; K Kuwano; C C Tseng; S Matsubara; M Matumoto; T Furudera
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.

Authors:  S Arai; Y Gohara; A Akashi; K Kuwano; M Nishimoto; T Yano; K Oizumi; K Takeda; T Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

10.  Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.

Authors:  T S Lucier; K Heitzman; S K Liu; P C Hu
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.